Inmunoterapia en Primera Linea. Avanzando en el tratamiento del CPNM

32 / 42

Reck M, et al. IMpower150 PFS analysis. 32
a Patients with a sensitising EGFR mutation or ALK translocation must have disease progression or intolerance of treatment with
one or more approved targeted therapies. b Atezolizumab: 1200 mg IV q3w. c Carboplatin: AUC 6 IV q3w.
d Paclitaxel: 200 mg/m2 IV q3w. e Bevacizumab: 15 mg/kg IV q3w.
IMpower150 study design
Arm A
Atezolizumab b +
Carboplatinc + Paclitaxeld
4 or 6 cycles
Atezolizumabb
Arm C (control)
Carboplatinc + Paclitaxeld
+ Bevacizumabe
4 or 6 cycles
Bevacizumabe Survival follow-up
Stage IV or
recurrent metastatic
non-squamous NSCLC
Chemotherapy-naivea
Tumour tissue available
for biomarker testing
Any PD-L1 IHC status
Stratification factors:
• Sex
• PD-L1 IHC expression
• Liver metastases
N = 1202
R
1:1:1
Arm B
Atezolizumab b +
Carboplatinc + Paclitaxeld
+ Bevacizumabe
4 or 6 cycles
Atezolizumabb
+
Bevacizumabe
Maintenance therapy
(no crossover permitted)
Treated with
atezolizumab
until PD by
RECIST v1.1
or loss of
clinical benefit
AND/OR
Treated with
bevacizumab
until PD by
RECIST v1.1
The principal question is to assess whether the addition of atezolizumab to Arm C provides clinical benefit